Navigation Links
Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
Date:9/13/2012

AMSTERDAM and IRVINE, Calif., Sept. 13, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that they will present five posters on genomic research studies in breast cancer at the American Society of Clinical Oncology (ASCO) 2012 Breast Cancer Symposium. The meeting will be held from September 13-15, 2012 at the Marriott Marquis in San Francisco, California. 

Agendia's Symphony™ suite of molecular diagnostic breast cancer tests, which have been available in an FFPE format since January of this year, enable physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy and targeted therapies, thereby providing benefits over existing treatment approaches for patients, physicians and payers.

Agendia's lead product, MammaPrint®, is the first and only diagnostic breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). Agendia's product development pipeline includes a further extension of its breast cancer Symphony suite as well as similar molecular diagnostic products for colon cancer. 

All of the abstracts listed below can currently be found online at www.ASCO.org. Presentation details are as follows (all times are in Pacific Time). 

Thursday, September 13, 2012

1. Poster Presentation: Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.

  • Lead Author: G. Viale, L. Slaets, F. De Snoo, L. J. van 't Veer, E. J. Rutgers, J. Bogaerts, L. Stork-Sloots, K. Engelen, L. Russo, P. Dell'Orto, F. Cardoso, M. J. Piccart-Gebhart
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall

2. Poster Presentation and Discussion: Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients. 

  • Lead Author: K. Yao, M. Turk, K. Kaul, J. Weaver, F. De Snoo, L. Stork-Sloots, M. Cristofanilli
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall 
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

3. Poster Presentation and Discussion: Response and long-term outcomes after neo-adjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping by MammaPrint and BluePrint. 

  • Lead Author: S. Gluck, F. De Snoo, J. Peeters, G. Somlo, L. Stork-Sloots, L. J. van 't Veer
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

4. Poster Presentation and Discussion: Central review of discordant samples for microarray based on ER, PR and HER2 and local IHC/FISH assessment worldwide from 827 patients. 

  • Lead Author: J. Wesseling, C. Tinterri, A. Sapino, F. Zanconati, M. Lutke Holzik, B. Nguyen, K. B. Deck, P. Querzoli, T. Perin, C. Giardina, G. Seitz, J. –M. Guinebretiere, J. Barone, T. Watanabe, F. De Snoo, L. Stork-Sloots, P. Cusumano
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

5. Poster Presentation and Discussion: Gene expression panel (TheraPrint) analyzed as predictors of response to neo-adjuvant chemotherapy (NCT) in patients (pts) with stage II-III and inflammatory breast cancer (BC). 

  • Lead Author: G. Somlo, F. De Snoo, J. Peeters, L. Stork-Sloots, I. Simon, K. Robinson
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

About Agendia
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

For more information, please visit www.agendia.com.

For further information, please contact:

Post+Beam
Melissa Hurley
Tel: +1 646 442 2773
E-mail: hurley@postandbeam.is 


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
4. Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):